Abstract

Mesenchymal stromal cells (MSCs) are inherently immunomodulatory through production of inhibiting soluble factors and expression of immunosuppressive cell surface markers. We tested whether activated MSCs qualify for the induction of antigen-specific immune regulation. Bone marrow derived human MSCs were activated by interferon-γ and analyzed for antigen uptake and processing and immune regulatory features including phenotype, immunosuppressive capacity, and metabolic activity. To assess whether activated MSC can modulate adaptive immunity, MSCs were pulsed with islet auto-antigen (GAD65) peptide to stimulate GAD65-specific T-cells. We confirm that inflammatory activation of MSCs increased HLA class II, PD-L1, and intracellular IDO expression, whereas co-stimulatory molecules including CD86 remained absent. MSCs remained locked in their metabolic phenotype, as activation did not alter glycolytic function or mitochondrial respiration. MSCs were able to uptake and process protein. Activated HLA-DR3-expressing MSCs pulsed with GAD65 peptide inhibited proliferation of HLA-DR3-restricted GAD65-specific T-cells, while this HLA class II expression did not induce cellular alloreactivity. Conditioning of antigen-specific T-cells by activated and antigen-pulsed MSCs prevented T-cells to proliferate upon subsequent activation by dendritic cells, even after removal of the MSCs. In sum, activation of MSCs with inflammatory stimuli turns these cells into suppressive cells capable of mediating adaptive regulation of proinflammatory pathogenic T-cells.

Highlights

  • Mesenchymal stromal cells (MSCs) are non-hematopoietic cells that can be sourced from various tissues, including bone marrow [1]

  • We provide in vitro evidence that activated MSCs can take up and process antigens and upregulate HLA class II expression, collectively granting MSCs the conditions necessary to transform into unconventional antigen-presenting cells

  • HLA-DR expression was increased after activation, this was not accompanied by an increase in activating co-stimulatory molecules CD86 and CD80

Read more

Summary

Introduction

Mesenchymal stromal cells (MSCs) are non-hematopoietic cells that can be sourced from various tissues, including bone marrow [1]. They have been widely used clinically to improve the outcome of hematopoietic stem cell and solid organ transplants and to treat graft-vs -host disease [2, 3]. The. Frontiers in Immunology | www.frontiersin.org van Megen et al. Activated MSCs Regulate Adaptive Immunity immunomodulative properties of MSCs make these excellent candidates for cellular therapies targeting inflammatory and autoimmune disorders, including type 1 diabetes (T1D) [3]. T1D is a T-cell mediated autoimmune disease in which autoreactive Tcells selectively kill insulin-producing beta-cells in the pancreas [4]. MSCs have been investigated for their potential to regenerate beta-cells, or to contribute to regeneration of beta-cells, which is another strategy to counter T1D [5, 6]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call